Share on StockTwits

XenoPort (NASDAQ:XNPT) shares rose 11.9% during mid-day trading on Thursday following insider buying activity, ARN reports. The company traded as high as $4.38 and last traded at $4.24, with a volume of 486,135 shares trading hands. The stock had previously closed at $3.79.

Specifically, Director John Gordon Freund purchased 12,500 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 3rd. The shares were purchased at an average cost of $3.93 per share, with a total value of $49,125.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on XNPT. Analysts at Jefferies Group reiterated a “buy” rating on shares of XenoPort in a research note on Thursday, May 15th. They now have a $6.00 price target on the stock. Separately, analysts at RBC Capital cut their price target on shares of XenoPort from $12.00 to $10.00 in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $6.22.

The stock has a 50-day moving average of $3.91 and a 200-day moving average of $5.2. The company’s market cap is $260.6 million.

XenoPort (NASDAQ:XNPT) last announced its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.32) by $0.04. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $3.86 million. During the same quarter last year, the company posted ($0.50) earnings per share. XenoPort’s revenue was up 639.1% compared to the same quarter last year. On average, analysts predict that XenoPort will post $-1.46 earnings per share for the current fiscal year.

XenoPort, Inc is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.